fbpx

Weekly Top News – Psoriasis– January 13, 2020

January 13, 2020

bimekizumab (UCB4940) / UCB
Bimekizumab clinical trial estimate: Presentation of full data from P3 BE SURE trial (NCT03412747) for psoriasis at ESDR (September 02-September 05, 2020) (J.P. Morgan) – Jan 9, 2020 – A subscription to Thomson ONE is required to gain full access to report 68594462; Page no: 129; REPORT TITLE: “EU Pharma & Biotech: Sector set to top the medal table in an Olympic year”; AUTHOR: Vosser, Richard, et al; DATE: 1/06/2020

 

Cosentyx (secukinumab) / Novartis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (clinicaltrials.gov) – Jan 9, 2020 – P3; N=204; Completed; Sponsor: Novartis Pharmaceuticals; Active, not recruiting –> Completed

 

Qletli (adalimumab biosimilar) / Bio-Thera Solutions
Bio-Thera Solutions launches first commercial product, Qletli (格乐立), in China (Businesswire) – Jan 10, 2020 – “Bio-Thera Solutions, Ltd…today announced that QLETLI® (格乐立®), a biosimilar to Humira® (adalimumab), is now available in China. QLETLI® (格乐立®), the first adalimumab biosimilar approved by the China National Medical Products Administration (NMPA), is authorized for the treatment of three autoimmune diseases: rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.”

 

Otezla (apremilast) / Amgen
Otezla sales projection: $2.35B by 2020 (GlobalData) – Jan 7, 2020 – A subscription to Thomson ONE is required to gain full access to report 67598474 Page no: 66; REPORT TITLE: ” Cipher Pharmaceuticals Inc (CPH) – Financial analysis review”; AUTHOR: GlobalData ; DATE: 12/30/2019

No Comments

Post a Comment

Comment
Name
Email
Website